LIFECORE BIOMEDICAL, INC. Cost of Revenue
LIFECORE BIOMEDICAL, INC. (LFCR) reported Cost of Revenue of $22.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $22.09M.
- LIFECORE BIOMEDICAL, INC. cost of goods and services sold for the quarter ending 2026-03-31 was $18.73M.
- LIFECORE BIOMEDICAL, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $23.32M.
- LIFECORE BIOMEDICAL, INC. cost of goods and services sold for the quarter ending 2025-05-25 was $22.46M, a 8.96% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. cost of goods and services sold for fiscal 2025 was $88.57M, a 2.50% increase from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. cost of goods and services sold for fiscal 2024 was $86.41M, a 14.78% increase from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. cost of goods and services sold for fiscal 2023 was $75.28M, a 4.27% increase from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. cost of goods and services sold for fiscal 2022 was $72.20M, a 16.58% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 1 month | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 7 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $22.09M 10-Q · filed 2026-08-05 | $40.82M 10-Q · filed 2026-08-05 | ||||||||
| 2026-03-31 | $18.73M 10-Q · filed 2026-05-06 | |||||||||
| 2025-12-31 | $51.83M 10-KT · filed 2026-03-16 | |||||||||
| 2025-09-30 | $23.32M 10-Q · filed 2025-11-06 | |||||||||
| 2025-06-30 | $5.53M 10-KT · filed 2026-03-16 | |||||||||
| 2025-05-25 | $22.46M 10-Q · filed 2026-08-05 | $47.77M 10-Q · filed 2026-08-05 | $69.25M derived: sum of 3 quarters · filed 2026-08-05 | $88.57M 10-KT · filed 2026-03-16 | ||||||
| 2025-02-23 | $25.31M 10-Q · filed 2026-05-06 | $46.79M derived: sum of 2 quarters · filed 2026-05-06 | $66.11M 10-Q · filed 2025-04-03 | $86.72M derived: sum of 4 quarters · filed 2026-05-06 | ||||||
| 2024-12-31 | $46.63M 10-KT · filed 2026-03-16 | |||||||||
| 2024-11-24 | $21.48M 10-Q · filed 2025-01-02 | $40.80M 10-Q · filed 2025-01-02 | $61.41M derived: sum of 3 quarters · filed 2026-03-16 | $85.22M derived: sum of 4 quarters · filed 2026-03-16 | ||||||
| 2024-08-25 | $19.32M 10-Q · filed 2025-11-06 | $39.93M derived: sum of 2 quarters · filed 2026-03-16 | $63.74M derived: sum of 3 quarters · filed 2026-03-16 | $83.94M derived: sum of 4 quarters · filed 2026-03-16 | ||||||
| 2024-05-26 | $20.61M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $44.42M derived: sum of 2 quarters · filed 2026-03-16 | $64.62M derived: sum of 3 quarters · filed 2026-03-16 | $86.41M 10-KT · filed 2026-03-16 | ||||||
| 2024-02-25 | $23.81M 10-Q · filed 2025-04-03 | $44.00M derived: sum of 2 quarters · filed 2025-04-03 | $65.80M 10-Q · filed 2025-04-03 | $89.16M derived: sum of 4 quarters · filed 2025-04-03 | ||||||
| 2023-11-26 | $20.19M 10-Q · filed 2025-01-02 | $41.99M 10-Q · filed 2025-01-02 | $65.35M derived: sum of 3 quarters · filed 2025-01-02 | $83.34M derived: sum of 4 quarters · filed 2025-01-02 | ||||||
| 2023-08-27 | $21.79M 10-Q · filed 2024-10-04 | $45.16M derived: sum of 2 quarters · filed 2024-10-04 | $63.15M derived: sum of 3 quarters · filed 2024-10-04 | $79.33M derived: sum of 4 quarters · filed 2024-10-04 | ||||||
| 2023-05-28 | $23.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-26 | $41.35M derived: sum of 2 quarters · filed 2024-08-26 | $57.54M derived: sum of 3 quarters · filed 2024-08-26 | $75.28M 10-K · filed 2024-08-26 | ||||||
| 2023-02-26 | $17.99M 10-Q · filed 2024-08-09 | $21.62M 10-Q · filed 2023-06-02 | $34.17M derived: sum of 2 quarters · filed 2024-08-09 | $51.92M 10-Q · filed 2024-08-09 | $58.18M 10-Q · filed 2023-06-02 | $65.61M derived: sum of 4 quarters · filed 2024-08-26 | ||||
| 2022-11-27 | $16.18M 10-Q · filed 2024-08-09 | $31.69M 10-Q · filed 2023-03-16 | $33.93M 10-Q · filed 2024-08-09 | $68.80M 10-Q · filed 2023-03-16 | $47.63M derived: sum of 3 quarters · filed 2024-08-26 | $71.22M derived: sum of 4 quarters · filed 2024-08-26 | ||||
| 2022-08-28 | $17.75M 10-Q · filed 2024-08-09 | $37.53M 10-Q · filed 2022-10-07 | $31.44M derived: sum of 2 quarters · filed 2024-08-26 | $55.03M derived: sum of 3 quarters · filed 2024-08-26 | $69.18M derived: sum of 4 quarters · filed 2024-08-26 | |||||
| 2022-05-29 | $13.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-26 | $37.29M derived: sum of 2 quarters · filed 2024-08-26 | $51.43M derived: sum of 3 quarters · filed 2024-08-26 | $72.20M 10-K · filed 2024-08-26 | $135.42M 10-K · filed 2022-09-14 | |||||
| 2022-02-27 | $23.59M 10-K · filed 2024-03-20 | $39.18M 10-Q · filed 2022-04-07 | $37.74M derived: sum of 2 quarters · filed 2024-03-20 | $58.51M 10-Q · filed 2023-06-02 | $99.11M 10-Q · filed 2022-04-07 | $25.72M derived: sum of 4 quarters · filed 2024-03-20 | ||||
| 2021-11-28 | $14.14M 10-K · filed 2024-03-20 | $116.50M 10-Q · filed 2022-01-07 | $59.93M 10-Q · filed 2023-03-16 | $227.77M 10-Q · filed 2022-01-07 | $2.13M derived: sum of 3 quarters · filed 2024-03-20 | $19.00M derived: sum of 4 quarters · filed 2024-03-20 | ||||
| 2021-08-29 | $16.79M 10-K · filed 2024-03-20 | $111.27M 10-Q · filed 2021-10-05 | -$12.02M derived: sum of 2 quarters · filed 2024-03-20 | $4.86M derived: sum of 3 quarters · filed 2024-03-20 | $17.88M derived: sum of 4 quarters · filed 2024-03-20 | |||||
| 2021-05-30 | -$28.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$11.93M derived: sum of 2 quarters · filed 2024-03-20 | $1.09M derived: sum of 3 quarters · filed 2024-03-20 | $61.94M 10-K · filed 2024-03-20 | $462.69M 10-K · filed 2021-07-29 | |||||
| 2021-02-28 | $16.88M 10-K · filed 2024-03-20 | $118.09M 10-Q · filed 2021-04-08 | $29.89M derived: sum of 2 quarters · filed 2024-03-20 | $90.74M 10-Q · filed 2022-04-07 | $347.66M 10-Q · filed 2021-04-08 | -$215.38M derived: sum of 4 quarters · filed 2024-03-20 | ||||
| 2020-11-29 | $13.02M 10-K · filed 2024-03-20 | $110.27M 10-Q · filed 2021-01-07 | $229.56M 10-Q · filed 2022-01-07 | -$232.26M derived: sum of 3 quarters · filed 2024-03-20 | -$99.38M derived: sum of 4 quarters · filed 2024-03-20 | |||||
| 2020-08-30 | $17.38M 10-K · filed 2024-03-20 | $119.30M 10-Q · filed 2020-10-07 | -$245.28M derived: sum of 2 quarters · filed 2024-03-20 | -$112.40M derived: sum of 3 quarters · filed 2024-03-20 | $14.68M derived: sum of 4 quarters · filed 2024-03-20 | |||||
| 2020-05-31 | -$262.66M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-16 | -$129.78M derived: sum of 2 quarters · filed 2023-03-16 | -$2.70M derived: sum of 3 quarters · filed 2023-03-16 | $120.68M 10-K/A · filed 2023-03-16 | $515.38M 10-K · filed 2020-08-14 | |||||
| 2020-02-23 | $132.88M 10-Q · filed 2021-04-08 | $259.96M derived: sum of 2 quarters · filed 2021-04-08 | $383.34M 10-Q · filed 2021-04-08 | $509.91M derived: sum of 4 quarters · filed 2021-07-29 | ||||||
| 2019-11-24 | $127.08M 10-Q · filed 2021-01-07 | $250.46M 10-Q · filed 2021-01-07 | $377.02M derived: sum of 3 quarters · filed 2021-07-29 | $511.01M derived: sum of 4 quarters · filed 2021-07-29 | ||||||
| 2019-08-25 | $123.38M 10-Q · filed 2020-10-07 | $249.95M derived: sum of 2 quarters · filed 2021-07-29 | $383.93M derived: sum of 3 quarters · filed 2021-07-29 | $491.60M derived: sum of 4 quarters · filed 2021-07-29 | ||||||
| 2019-05-26 | $126.57M derived: 10-K 12 month − 10-Q 9 month · filed 2021-07-29 | $260.55M derived: sum of 2 quarters · filed 2021-07-29 | $368.23M derived: sum of 3 quarters · filed 2021-07-29 | $476.56M 10-K · filed 2021-07-29 | ||||||
| 2019-02-24 | $133.99M 10-Q · filed 2020-04-03 | $134.47M 10-Q · filed 2019-04-04 | $241.66M derived: sum of 2 quarters · filed 2020-04-03 | $349.99M 10-Q · filed 2020-04-03 | $351.12M 10-Q · filed 2019-04-04 | $466.25M derived: sum of 4 quarters · filed 2020-08-14 | ||||
| 2018-11-25 | $107.67M 10-Q · filed 2020-01-02 | $108.32M 10-Q · filed 2019-01-07 | $216.00M 10-Q · filed 2020-01-02 | $216.65M 10-Q · filed 2019-01-07 | $332.27M derived: sum of 3 quarters · filed 2020-08-14 | $457.37M derived: sum of 4 quarters · filed 2020-08-14 | ||||
| 2018-08-26 | $108.33M 10-Q · filed 2019-10-03 | $224.60M derived: sum of 2 quarters · filed 2020-08-14 | $349.70M derived: sum of 3 quarters · filed 2020-08-14 | $457.24M derived: sum of 4 quarters · filed 2020-08-14 | ||||||
| 2018-05-27 | $116.27M derived: 10-K 12 month − 10-Q 9 month · filed 2020-08-14 | $241.37M derived: sum of 2 quarters · filed 2020-08-14 | $348.91M derived: sum of 3 quarters · filed 2020-08-14 | $445.89M 10-K · filed 2020-08-14 | ||||||
| 2018-02-25 | $125.10M 10-Q · filed 2019-04-04 | $232.64M derived: sum of 2 quarters · filed 2019-04-04 | $329.62M 10-Q · filed 2019-04-04 | |||||||
| 2017-11-26 | $107.54M 10-Q · filed 2019-01-07 | $204.52M 10-Q · filed 2019-01-07 | ||||||||
| 2017-08-27 | $96.98M 10-Q · filed 2018-10-05 | |||||||||
| 2017-05-28 | $390.56M 10-K · filed 2019-08-01 | |||||||||
| 2016-05-29 | $410.14M 10-K · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |